Welcome to Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly-owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune/Roche) having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013.

Latest News and Press Releases:
5/15/2013	Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
5/8/2013	Array BioPharma to Present at the Bank of America Merrill Lynch Healthcare Conference and the UBS Global Healthcare Conference
5/6/2013	Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
5/6/2013	Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer